Terms: = Bone cancer AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Treatment
80 results:
1. A personalized medicine approach identifies enasidenib as an efficient treatment for idh2 mutant chondrosarcoma.
Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
[TBL] [Abstract] [Full Text] [Related]
2. treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.
Streuer A; Jann JC; Boch T; Mossner M; Riabov V; Schmitt N; Altrock E; Xu Q; Demmerle M; Nowak V; Oblaender J; Palme I; Weimer N; Rapp F; Metzgeroth G; Hecht A; Höger T; Merz C; Hofmann WK; Nolte F; Nowak D
Ann Hematol; 2024 Apr; 103(4):1221-1233. PubMed ID: 38413410
[TBL] [Abstract] [Full Text] [Related]
3. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.
Nelde A; Schuster H; Heitmann JS; Bauer J; Maringer Y; Zwick M; Volkmer JP; Chen JY; Stanger AMP; Lehmann A; Appiah B; Märklin M; Rücker-Braun E; Salih HR; Roerden M; Schroeder SM; Häring MF; Schlosser A; Schetelig J; Schmitz M; Boerries M; Köhler N; Lengerke C; Majeti R; Weissman IL; Rammensee HG; Walz JS
Blood Cancer Discov; 2023 Nov; 4(6):468-489. PubMed ID: 37847741
[TBL] [Abstract] [Full Text] [Related]
4. Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.
Shen X; Dong P; Kong J; Sun N; Wang F; Sang L; Xu Y; Zhang M; Chen X; Guo R; Wang S; Lin Q; Jiang Z; Xu S; Zhang C; Bian Z; Wang W; Guo R
Cell Biochem Funct; 2023 Dec; 41(8):1343-1356. PubMed ID: 37823726
[TBL] [Abstract] [Full Text] [Related]
5. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V; Chawla SP; Conley AP; Wilky BA; Tolcher A; Lakhani NJ; Berz D; Andrianov V; Crago W; Holcomb M; Hussain A; Veldstra C; Kalabus J; O'Neill B; Senne L; Rowell E; Heidt AB; Willis KM; Eckelman BP
Clin Cancer Res; 2023 Aug; 29(16):2988-3003. PubMed ID: 37265425
[TBL] [Abstract] [Full Text] [Related]
7. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
[TBL] [Abstract] [Full Text] [Related]
8. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
Palubeckaitė I; Venneker S; van den Akker BEWM; Briaire-de Bruijn IH; Boveé JVMG
Clin Orthop Relat Res; 2023 Mar; 481(3):608-619. PubMed ID: 36729612
[TBL] [Abstract] [Full Text] [Related]
9. Olfactory Neuroblastoma: Morphological Reappraisal and Molecular Insights with Quantum Leap in Clinical Perspectives.
Bell D; Brandea AI; Hanna EY
Curr Oncol Rep; 2023 Jan; 25(1):11-18. PubMed ID: 36449116
[TBL] [Abstract] [Full Text] [Related]
10. Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2.
Chen X; Yang P; Qiao Y; Ye F; Wang Z; Xu M; Han X; Song L; Wu Y; Ou WB
Sci Rep; 2022 Nov; 12(1):18830. PubMed ID: 36335201
[TBL] [Abstract] [Full Text] [Related]
11. Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma.
Wu L; Wu W; Zhang J; Zhao Z; Li L; Zhu M; Wu M; Wu F; Zhou F; Du Y; Chai RC; Zhang W; Qiu X; Liu Q; Wang Z; Li J; Li K; Chen A; Jiang Y; Xiao X; Zou H; Srivastava R; Zhang T; Cai Y; Liang Y; Huang B; Zhang R; Lin F; Hu L; Wang X; Qian X; Lv S; Hu B; Zheng S; Hu Z; Shen H; You Y; Verhaak RGW; Jiang T; Wang Q
Cancer Discov; 2022 Dec; 12(12):2820-2837. PubMed ID: 36122307
[TBL] [Abstract] [Full Text] [Related]
12. Impact of idh1 and idh2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
[TBL] [Abstract] [Full Text] [Related]
13. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
[TBL] [Abstract] [Full Text] [Related]
14. Targeted therapy with the mutant idh2 inhibitor enasidenib for high-risk idh2-mutant myelodysplastic syndrome.
DiNardo CD; Venugopal S; Lachowiez C; Takahashi K; Loghavi S; Montalban-Bravo G; Wang X; Carraway H; Sekeres M; Sukkur A; Hammond D; Chien K; Maiti A; Masarova L; Sasaki K; Alvarado Y; Kadia T; Short NJ; Daver N; Borthakur G; Ravandi F; Kantarjian HM; Patel B; Dezern A; Roboz G; Garcia-Manero G
Blood Adv; 2023 Jun; 7(11):2378-2387. PubMed ID: 35973199
[TBL] [Abstract] [Full Text] [Related]
15. Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of midh1 Mutant Tumours.
Weber V; Arnaud L; Dukic-Stefanovic S; Wenzel B; Roux V; Chezal JM; Lai TH; Teodoro R; Kopka K; Miot-Noirault E; Deuther-Conrad W; Maisonial-Besset A
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744895
[TBL] [Abstract] [Full Text] [Related]
16. idh1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract] [Full Text] [Related]
17. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract] [Full Text] [Related]
18. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
[TBL] [Abstract] [Full Text] [Related]
19. Emerging concepts in sinonasal tumor research.
Lopez DC; Wadley AE; London NR
Curr Opin Otolaryngol Head Neck Surg; 2022 Feb; 30(1):33-39. PubMed ID: 34958321
[TBL] [Abstract] [Full Text] [Related]
20. Clinical Outcomes of Surgical Correction and Fusion for Postlaminectomy Kyphosis Following Spinal Tumor Resection in Adolescent Patients.
Pan W; Li J; Qiu Y; Zhu Z; Zhu W; Liu Z
J Pediatr Orthop; 2022 Mar; 42(3):138-143. PubMed ID: 34608040
[TBL] [Abstract] [Full Text] [Related]
[Next]
